Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.

The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting Qadan, M. n., Kothary, N. n., Sangro, B. n., Palta, M. n. 2020; 40: 1–8

Abstract

Hepatocellular carcinoma (HCC) is the sixth most common cancer and third leading cause of cancer-related death worldwide. HCC is also is a tumor with a distinct ability to invade and grow within the hepatic vasculature. Approximately 20% of patients with HCC have macrovascular invasion (MVI) at the time of diagnosis. MVI is associated with dismal prognosis, with median survival ranging from 2 to 5 months. Current staging systems designate MVI as advanced disease. Recent advances in multimodal approaches, including systemic therapies, radiation therapy, liver-directed therapies, and surgical approaches, in the treatment of HCC with MVI have rendered this disease process more treatable with improved outcomes and are discussed here.

View details for DOI 10.1200/EDBK_280811

View details for PubMedID 32213090